Pharmaceuticals

Gastroesophageal Reflux Disease Therapeutics Market Growth Opportunities: Insights from 2025–2029

November 9, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Gastroesophageal Reflux Disease Therapeutics Market Expected To Expand Between 2025 And 2029?

The gastroesophageal reflux disease therapeutics market size has shown steady expansion in recent years. It is anticipated to increase from $5.93 billion in 2024 to $6.08 billion in 2025, achieving a compound annual growth rate (CAGR) of 2.5%. The historical growth of this market can be attributed to various factors such as changing lifestyles and dietary habits, an aging population, increased awareness and diagnosis, prevailing stressful lifestyles, and a rise in obesity rates.

The gastroesophageal reflux disease therapeutics market size is projected to demonstrate robust expansion over the next few years. It is forecast to reach $7.74 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.2%. The anticipated increase during the forecast period is fueled by a rising demand for new therapies, an expanding geriatric population, the adoption of personalized medicine approaches, a heightened focus on non-pharmacological interventions, and the emergence of biologics and groundbreaking treatments. Significant trends expected in this period include alternative therapies and mind-body practices, augmented research into gut health, the advent of patient-centric care models, targeted marketing to raise GERD awareness, and the integration of digital health tools.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp

What Are The Main Drivers Boosting The Gastroesophageal Reflux Disease Therapeutics Industry’s Expansion?

The increasing occurrence of gastroesophageal reflux disease is projected to fuel the expansion of the gastroesophageal reflux disease therapeutics market in the future. This chronic ailment involves stomach acid flowing back into the esophagus, leading to symptoms like heartburn, regurgitation, and possible complications. Treatments for gastroesophageal reflux disease (GERD) assist in alleviating and controlling acid reflux symptoms by balancing gut pH, managing inflammation, and enhancing esophageal function. For example, data from September 2022, as per an article from WebMed, a US-based online health information publisher, indicates that over 60 million American adults experience heartburn monthly, with more than 15 million suffering daily. Additionally, statistics released in July 2022 by the National Library of Medicine, a US federal medical library, show that GERD is among the most frequently diagnosed digestive conditions in the United States, affecting 20% of the population. This creates a considerable economic burden through direct and indirect costs and adversely impacts quality of life. Consequently, the widespread occurrence of gastroesophageal reflux disease is anticipated to stimulate the expansion of the gastroesophageal reflux disease therapeutics market.

What Are The Major Segment Categories Driving The Gastroesophageal Reflux Disease Therapeutics Market Growth?

The gastroesophageal reflux disease therapeutics market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class

3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets

4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

Subsegments:

1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents

2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents

How Are Emerging Market Trends Shaping The Gastroesophageal Reflux Disease Therapeutics Industry Landscape?

A prominent trend gaining traction within the gastroesophageal reflux disease therapeutics market is product innovation. Leading companies engaged in the gastroesophageal reflux disease therapeutics market are concentrating on developing novel medications to maintain their competitive standing. An illustrative example is the launch of VOQUEZNA (vonoprazan) by Phathom Pharmaceuticals, a US-based biopharmaceutical firm, in November 2023. This potassium-competitive acid blocker received approval for treating and maintaining all severities of erosive esophagitis, in addition to reducing heartburn linked to both erosive and non-erosive GERD. Clinical studies demonstrated impressive results, indicating a 93% healing rate among patients receiving the 20 mg dosage, which surpassed the 85% achieved by the conventional proton pump inhibitor (PPI) lansoprazole.

Who Are The Top Performing Companies In The Gastroesophageal Reflux Disease Therapeutics Market In Recent Years?

Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Which Regional Markets Are Contributing Most To The Gastroesophageal Reflux Disease Therapeutics Industry Expansion?

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gastroesophageal Reflux Disease Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp

Browse Through More Reports Similar to the Global Gastroesophageal Reflux Disease Therapeutics Market 2025, By The Business Research Company

Real Time Location Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/real-time-location-systems-global-market-report

Rail Asset Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rail-asset-management-global-market-report

Wireless Intercom Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wireless-intercom-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795